These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10357210)

  • 21. High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance.
    Nguyen PC; Lewis KB; Ettinger RA; Schuman JT; Lin JC; Healey JF; Meeks SL; Lollar P; Pratt KP
    Blood; 2014 Apr; 123(17):2732-9. PubMed ID: 24591205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human factor VIII inhibitor alloantibodies with a C2 epitope inhibit factor Xa-catalyzed factor VIII activation: a new anti-factor VIII inhibitory mechanism.
    Nogami K; Shima M; Nishiya K; Sakurai Y; Tanaka I; Giddings JC; Saenko EL; Yoshioka A
    Thromb Haemost; 2002 Mar; 87(3):459-65. PubMed ID: 11916079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab.
    Kessel C; Königs C; Linde R; Escuriola-Ettinghausen C; Stoll H; Klingebiel T; Dietrich U; Kreuz W
    Mol Immunol; 2008 Nov; 46(1):8-15. PubMed ID: 18715645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene.
    Pashov AD; Calvez T; Gilardin L; Maillère B; Repessé Y; Oldenburg J; Pavlova A; Kaveri SV; Lacroix-Desmazes S
    Haemophilia; 2014 Mar; 20(2):176-84. PubMed ID: 24118514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect.
    Nogami K; Shima M; Nakai H; Tanaka I; Suzuki H; Morichika S; Shibata M; Saenko EL; Scandella D; Giddings JC; Yoshioka A
    Br J Haematol; 1999 Oct; 107(1):196-203. PubMed ID: 10520041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.
    Meeks SL; Healey JF; Parker ET; Barrow RT; Lollar P
    Blood; 2007 Dec; 110(13):4234-42. PubMed ID: 17848617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope.
    Dimitrov JD; Roumenina LT; Plantier JL; Andre S; Saboulard D; Meslier Y; Planchais C; Jacquemin M; Saint-Remy JM; Atanasov BP; Kaveri SV; Lacroix-Desmazes S
    J Thromb Haemost; 2010 Jul; 8(7):1524-31. PubMed ID: 20374449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.
    Astermark J; Voorberg J; Lenk H; DiMichele D; Shapiro A; Tjönnfjord G; Berntorp E
    Haemophilia; 2003 Sep; 9(5):567-72. PubMed ID: 14511295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The diversity of the immune response to the A2 domain of human factor VIII.
    Markovitz RC; Healey JF; Parker ET; Meeks SL; Lollar P
    Blood; 2013 Apr; 121(14):2785-95. PubMed ID: 23349389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mapping of FVIII inhibitor epitopes using cellulose-bound synthetic peptide arrays.
    Kopecky EM; Greinstetter S; Pabinger I; Buchacher A; Römisch J; Jungbauer A
    J Immunol Methods; 2006 Jan; 308(1-2):90-100. PubMed ID: 16376372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action.
    Saenko EL; Ananyeva NM; Kouiavskaia DV; Khrenov AV; Anderson JA; Shima M; Qian J; Scott D
    Haemophilia; 2002 Jan; 8(1):1-11. PubMed ID: 11886458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes.
    Suzuki H; Shima M; Arai M; Kagawa K; Fukutake K; Kamisue S; Nakai H; Morichika S; Tanaka I; Inoue M; Gale K; Tuddenham EG; Yoshioka A
    Thromb Haemost; 1997 May; 77(5):862-7. PubMed ID: 9184393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two classes of germline genes both derived from the V(H)1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII.
    van den Brink EN; Bril WS; Turenhout EA; Zuurveld M; Bovenschen N; Peters M; Yee TT; Mertens K; Lewis DA; Ortel TL; Lollar P; Scandella D; Voorberg J
    Blood; 2002 Apr; 99(8):2828-34. PubMed ID: 11929772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes.
    Gilles JG; Lavend'homme R; Peerlinck K; Jacquemin MG; Hoylaerts M; Jorieux S; Mazurier C; Vermylen J; Saint-Remy JM
    Thromb Haemost; 1999 Jul; 82(1):40-5. PubMed ID: 10456452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies.
    Scandella D
    Vox Sang; 1999; 77 Suppl 1():17-20. PubMed ID: 10529680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII.
    Jones TD; Phillips WJ; Smith BJ; Bamford CA; Nayee PD; Baglin TP; Gaston JS; Baker MP
    J Thromb Haemost; 2005 May; 3(5):991-1000. PubMed ID: 15869596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display.
    Mullaney BP; Pallavicini MG; Marks JD
    Infect Immun; 2001 Oct; 69(10):6511-4. PubMed ID: 11553596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fine epitope mapping of monoclonal antibodies to the NH2-terminal part of von Willebrand factor (vWF) by using recombinant and synthetic peptides: interest for the localization of the factor VIII binding domain.
    Jorieux S; Gaucher C; Piétu G; Chérel G; Meyer D; Mazurier C
    Br J Haematol; 1994 May; 87(1):113-8. PubMed ID: 7524613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor.
    Villard S; Lacroix-Desmazes S; Kieber-Emmons T; Piquer D; Grailly S; Benhida A; Kaveri SV; Saint-Remy JM; Granier C
    Blood; 2003 Aug; 102(3):949-52. PubMed ID: 12676786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII.
    Healey JF; Lubin IM; Nakai H; Saenko EL; Hoyer LW; Scandella D; Lollar P
    J Biol Chem; 1995 Jun; 270(24):14505-9. PubMed ID: 7540171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.